ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1027

A Novel IL-1 Mediated Autoinflammatory Disease Caused By a Specific Gain-of-Function Mutation in Dysferlin

Farzana Bhuyan1, Adriana Almeida de Jesus1, Gina A. Montealegre Sanchez1, Deborah Consolini2, Ronit Herzog3, Steven Holland4 and Raphaela Goldbach-Mansky1, 1Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, 2A.I.duPont Hospital for Children, Wilmington, DE, 3NYU Langone Medical Center, New York, NY, 4Division of Intramural Research, NIAID/NIH, Bethesda, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Autoinflammation and innate immunity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Innate Immunity Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Genetically defined IL-1 mediated autoinflammatory diseases are caused by monogenic defects that regulate inflammasome activity. By whole exome sequencing (WES) analysis we identified one de novo mutation in DYSF, encoding dysferlin, in 2 unrelated patients (pts.) with systemic inflammation and sterile pulmonary abscesses. Unlike dysferlin mutations that cause muscular dystrophies, the patients have no muscle disease. A robust clinical response to IL-1 blockade suggested a link to overproduction of IL-1. We studied monocytes and neutrophils to assess the mechanism of the IL-1 dependent inflammation. The aim of our study is to understand the role of DYSF on the upregulation of IL-1 production and the development of lung abscesses.

Methods: Flowcytometry, ELISA, cytokine array, survival assay and immunofluorescence techniques were used to study monocyte and neutrophil function in patients and controls.

Results: Lipopolysaccharides (LPS) and ATP-stimulated IL-1 production in monocyte and monocyte-derived macrophages (MDM) was significantly higher in the DYSF pts. compared to IL-1 production in NOMID pts. (p=0.029) and healthy controls (HC) (p=0.038). Dysferlin colocalizes with NLRP3 and expression of Asc, and caspase-1 were increased in the DYSF pts. compared to healthy controls, which is linked to higher IL-1β production. Our data confirmed NLRP3 and Caspase-1 co-localization in patient monocytes as well. The development of sterile neutrophilic abscesses in the lung raised questions of the role of dysferlin in neutrophil activation and clearance. In contrast to MDMs, IL-1 was not upregulated in patient neutrophils, however MIF (5 fold) and IL-16 (2-3 fold) were significantly upregulated compare to HC and NOMID but not in monocytes or macrophages. Neutrophils had a higher survival rate and lower LDH release compared to healthy controls upon stimulation with LPS and ATP. Elevated MIF and IL-16 release may prevent neutrophil apoptosis and enhance persistence of sterile neutrophils in the lung. Mechanistic studies to explore these pathways are ongoing.

Conclusion: Consistent with clinical responses of IL-1 blocking treatment, our in vitro results confirm mutant monocytes and MDMs as the source for the high IL-1 production in two patient with a de novo mutation in dysferlin. Moreover, the upregulation of MIF and IL-16 in neutrophils from dysferlin patients but not NOMID patients or healthy controls and the impairment of neutrophil apoptosis may provide a mechanism to explain the development of sterile abscesses in the patients’ lungs. This is the first report that links dysferlin to the regulation of the NLRP3 inflammasome and to neutrophil survival and adds to a number of intracellular pathways that control inflammasome activation and suggest novel targets for treatment.

Acknowledgements: This work was supported by the NIH IRP of NIAID


Disclosure: F. Bhuyan, None; A. Almeida de Jesus, None; G. A. Montealegre Sanchez, None; D. Consolini, None; R. Herzog, None; S. Holland, None; R. Goldbach-Mansky, None.

To cite this abstract in AMA style:

Bhuyan F, Almeida de Jesus A, Montealegre Sanchez GA, Consolini D, Herzog R, Holland S, Goldbach-Mansky R. A Novel IL-1 Mediated Autoinflammatory Disease Caused By a Specific Gain-of-Function Mutation in Dysferlin [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-novel-il-1-mediated-autoinflammatory-disease-caused-by-a-specific-gain-of-function-mutation-in-dysferlin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-il-1-mediated-autoinflammatory-disease-caused-by-a-specific-gain-of-function-mutation-in-dysferlin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology